VSV-based Therapeutic Papilloma Vaccine

基于 VSV 的治疗性乳头状瘤疫苗

• 批准号: 6897543
• 负责人: JANET L BRANDSMA
• 金额: $ 32.74万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-06-17 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6897543
• 关键词: Adenoviridae; Papillomavirus; Vesiculovirus; antigen antibody reaction; biotechnology; cancer prevention; cervix neoplasms; chimeric proteins; disease /disorder model; enzyme linked immunosorbent assay; human papillomavirus; immunization; immunoprecipitation; immunotherapy; laboratory rabbit; molecular cloning; nonhuman therapy evaluation; rabbit papillomavirus; remission /regression; sexually transmitted diseases; tumor antigens; ubiquitin; vaccine development; vector vaccine; virus envelope; western blottings

DESCRIPTION (provided by applicant): Human papillomavirus (HPV) infection of the cervix initiates the development of cervical cancer. Vaccination has the potential to prevent cervical cancer by preventing primary HPV infection and by eliminating persistent lesions. The ideal vaccine would induce therapeutic as well as protective immunity. The best animal model for therapeutic vaccine development is the cottontail rabbit papillomavirus (CRPV)-rabbit model. Live recombinant vesicular stomatitis viruses (rVSV) expressing foreign viral proteins have successfully protected animals against challenges with several human viruses. We recently generated an rVSV vector expressing the CRPV E6 tumor antigen and used it to vaccinate rabbits with well-established tumors (papillomas) in a preliminary experiment. The treatment induced dramatic therapeutic outcomes including the complete and permanent regression of all disease in some rabbits with a total papilloma burden of 4 cm3, as compared to no regression in the controls. The hypothesis of this application is that the rVSV-E6 vaccine can be improved to induce more rapid and more universal regression. It is based on the observation that the original vaccine expressed a relatively low level of E6 protein and that revaccination with the same rVSV-E6 was probably not effective, due to VSV-specific neutralizing antibodies induced by primary vaccination. The efficacy of the rVSV-E6 could also be improved by modifying the E6 gene to encode a ubiquitin-E6 fusion protein (UbE6), based on our findings, using CRPV DNA vaccines, that a UbE6 fused gene was markedly more effective than the unfused E6 gene. The specific aims are to repeat the preliminary experiment with larger group size and all appropriate controls; to determine if more rapid and more universal tumor clearance can be obtained using VSV vectors giving higher-level expression of E6 or expressing UbE6, using an efficient VSV-E6 boosting vector with the VSV envelope gene from a heterologous serotype, or using a completely heterologous viral vector (adenovirus). We will determine if the most effective therapeutic vaccine also induces protective immunity. The data provided by this investigation are likely to aid in the development a highly effective HPV vaccine to protect women against cervical cancer.

描述（由申请人提供）：子宫颈的人乳头瘤病毒（HPV）感染启动宫颈癌的发展。疫苗接种有可能通过预防原发性HPV感染并消除持续性病变来预防宫颈癌。理想的疫苗将诱导治疗和保护性免疫。治疗性疫苗开发的最佳动物模型是棉尾兔乳头瘤病毒（CRPV） - 兔模型。表达异物蛋白的活泡囊炎病毒（RVSV）成功地保护了动物免受几种人类病毒的挑战。我们最近生成了表达CRPV E6肿瘤抗原的RVSV载体，并将其用于在初步实验中用良好的肿瘤（乳头状瘤）接种兔子。该治疗引起了戏剧性的治疗结果，包括在某些兔子中的所有疾病的完全和永久消退，总乳头瘤负担为4 cm3，而对照组的不回归。该应用的假设是可以改进RVSV-E6疫苗以诱导更快，更普遍的回归。它基于这样的观察结果，即原始疫苗表达了相对较低的E6蛋白水平，并且由于初次疫苗引起的VSV特异性中和抗体，与相同RVSV-E6的重新接种可能无效。基于我们的发现，使用CRPV DNA疫苗，可以通过修改E6基因来编码E6基因以编码泛素-E6融合蛋白（UBE6）来提高RVSV-E6的功效，从而使UBE6 Fused基因比未使用的E6基因更有效。具体的目的是重复具有较大组大小和所有适当对照的初步实验。为了确定使用从异源血清型中使用VSV包膜基因的有效VSV-E6增强载体，使用有效的VSV-E6促进载体，使用有效的VSV-E6促进载体，或使用来自异源血清型的VSV-E6促进载体，或使用完全异源性病毒载体（adenovirus）。我们将确定最有效的治疗疫苗是否也诱导保护性免疫。这项研究提供的数据可能有助于开发一种高效的HPV疫苗，以保护妇女免受宫颈癌的侵害。